SG11201909710XA - Indole ahr inhibitors and uses thereof - Google Patents
Indole ahr inhibitors and uses thereofInfo
- Publication number
- SG11201909710XA SG11201909710XA SG11201909710XA SG11201909710XA SG 11201909710X A SG11201909710X A SG 11201909710XA SG 11201909710X A SG11201909710X A SG 11201909710XA SG 11201909710X A SG11201909710X A SG 11201909710XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- massachusetts
- april
- pct
- publication
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 25 October 2018 (25.10.2018) omit VIII °nolo VIII (10) International Publication Number WO 2018/195397 A3 WIPO I PCT (51) International Patent Classification: A01N 63/00 (2006.01) A61K 31/44 (2006.01) A61K 31/40 (2006.01) (21) International Application Number: PCT/US2018/028532 (22) International Filing Date: 20 April 2018 (20.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/488,476 21 April 2017 (21.04.2017) US 62/592,542 30 November 2017 (30.11.2017) US 62/658,454 16 April 2018 (16.04.2018) US (71) Applicant: KYN THERAPEUTICS [US/US]; 400 Tech- nology Square, 10th Floor, Cambridge, Massachusetts 02139 (US). (72) Inventors: CASTRO, Alfredo C.; 14 Kelly Drive, Woburn, Massachusetts 01801 (US). EVANS, Catherine Anne; 83 Jaques Street, Somerville, Massachusetts 02145 (US). (74) Agent: REID, Andrea L.C. et al.; One International Place, 100 Oliver Street, 40th Floor, Boston, Massachusetts 02110-2605 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (88) Date of publication of the international search report: 13 December 2018 (13.12.2018) O (57) : The present invention provides compounds useful as inhibitors of AHR, compositions thereof, and methods of using 0 the same. (54) Title: INDOLE AHR INHIBITORS AND USES THEREOF
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762488476P | 2017-04-21 | 2017-04-21 | |
| US201762592542P | 2017-11-30 | 2017-11-30 | |
| US201862658454P | 2018-04-16 | 2018-04-16 | |
| PCT/US2018/028532 WO2018195397A2 (en) | 2017-04-21 | 2018-04-20 | Indole ahr inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909710XA true SG11201909710XA (en) | 2019-11-28 |
Family
ID=63856153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909710X SG11201909710XA (en) | 2017-04-21 | 2018-04-20 | Indole ahr inhibitors and uses thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US10570138B2 (en) |
| EP (1) | EP3612030A4 (en) |
| JP (2) | JP7232244B2 (en) |
| KR (1) | KR102668371B1 (en) |
| CN (1) | CN110831600B (en) |
| AU (1) | AU2018256459B2 (en) |
| BR (1) | BR112019021992A2 (en) |
| CA (1) | CA3059939A1 (en) |
| CL (1) | CL2019003015A1 (en) |
| CO (1) | CO2019011584A2 (en) |
| IL (1) | IL270025B2 (en) |
| MX (1) | MX2019012431A (en) |
| SG (1) | SG11201909710XA (en) |
| TW (1) | TWI778050B (en) |
| WO (1) | WO2018195397A2 (en) |
| ZA (1) | ZA201906822B (en) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017377069B2 (en) | 2016-12-16 | 2020-07-23 | Janssen Pharmaceutica Nv | Small molecule inhibitors of the JAK family of kinases |
| JOP20190144A1 (en) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | Imidazopyrrolopyridine as inhibitors of the jak family of kinases |
| MX2019012431A (en) | 2017-04-21 | 2020-08-03 | Ikena Oncology Inc | Indole ahr inhibitors and uses thereof. |
| FR3066761B1 (en) | 2017-05-23 | 2020-10-30 | Centre Nat Rech Scient | NEW IONIC CHANNEL INHIBITORS |
| KR20200051646A (en) | 2017-08-17 | 2020-05-13 | 이케나 온콜로지, 인코포레이티드 | AHR inhibitors and uses thereof |
| EP3749669B1 (en) | 2018-02-06 | 2023-03-08 | Ideaya Biosciences, Inc. | Ahr modulators |
| WO2019156989A1 (en) * | 2018-02-06 | 2019-08-15 | Ideaya Biosciences, Inc. | COMPOUNDS AND METHODS FOR THE MODULATION OF AhR |
| TW202016110A (en) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Small molecule inhibitors of the jak family of kinases |
| EA202190654A1 (en) | 2018-09-07 | 2021-05-27 | Оцука Фармасьютикал Ко., Лтд. | HETEROCYCLIC CONNECTION |
| SG11202103796TA (en) * | 2018-10-16 | 2021-05-28 | Ikena Oncology Inc | Indole ahr inhibitors and uses thereof |
| EP3866797A1 (en) * | 2018-10-17 | 2021-08-25 | Magenta Therapeutics, Inc. | Methods of treating cancer with aryl hydrocarbon receptor antagonists |
| EA202191507A1 (en) * | 2018-11-30 | 2021-08-20 | Селулэрити Инк. | AROMATIC COMPOUNDS FOR USE TO ACTIVATE HEALTH STEM CELLS AND PROCESS CELLS |
| CN109813913B (en) * | 2019-01-31 | 2021-11-09 | 中国医学科学院肿瘤医院 | Use of aromatic hydrocarbon receptor (AhR) for predicting immunotherapy effect |
| BR112021016795A8 (en) * | 2019-02-27 | 2022-08-16 | Millennium Pharm Inc | ADMINISTRATION OF JUICE ACTIVATING ENZYME INHIBITOR AND CHECKPOINT INHIBITORS |
| US20220281824A1 (en) * | 2019-07-30 | 2022-09-08 | Oregon State University | Aryl hydrocarbon receptor activators |
| WO2021102288A1 (en) * | 2019-11-22 | 2021-05-27 | Senda Biosciences, Inc. | Pyridopyrimidinone derivatives as ahr antagonists |
| EP4065582A1 (en) | 2019-11-26 | 2022-10-05 | Ikena Oncology, Inc. | Polymorphic carbazole derivatives and uses thereof |
| JP2023503165A (en) * | 2019-11-26 | 2023-01-26 | エフ．ホフマン－ラ ロシュ アーゲー | 1,8-naphthyridin-2-one compounds for the treatment of autoimmune diseases |
| WO2021108469A1 (en) | 2019-11-26 | 2021-06-03 | Ikena Oncology, Inc. | Ahr inhibitors and uses thereof |
| TW202146416A (en) | 2019-12-11 | 2021-12-16 | 德商拜耳廠股份有限公司 | Pyrazolotriazines |
| MX2022008532A (en) | 2020-01-10 | 2022-09-09 | Ikena Oncology Inc | Ahr inhibitors and uses thereof. |
| JP2023515128A (en) | 2020-02-26 | 2023-04-12 | ジャガー セラピューティクス ピーティーイーリミテッド | Pyridopyrimidine Derivatives Useful for Modulating AHR Signaling |
| MX2022011826A (en) * | 2020-03-27 | 2022-10-18 | Dong A St Co Ltd | Aminopyrimidine derivatives and their use as aryl hydrocarbon receptor modulators. |
| US11857551B1 (en) | 2020-07-10 | 2024-01-02 | Ting Therapeutics Llc | Methods for the prevention and treatment of hearing loss |
| WO2022029063A1 (en) * | 2020-08-04 | 2022-02-10 | Bayer Aktiengesellschaft | Pyrido[1,2,4]triazolo[1,5-c]pyrimidin-5-amines |
| CN114369097B (en) * | 2020-10-15 | 2023-07-14 | 山东轩竹医药科技有限公司 | Heteroaromatic AhR inhibitors |
| IL302346A (en) | 2020-10-28 | 2023-06-01 | Ikena Oncology Inc | Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine |
| CN114644627B (en) * | 2020-12-18 | 2024-06-11 | 山东轩竹医药科技有限公司 | AhR inhibitors and uses thereof |
| CN112656789A (en) * | 2020-12-31 | 2021-04-16 | 中国科学院生态环境研究中心 | Application of FICZ in inhibiting tumor cell migration |
| CN114805361B (en) * | 2021-01-17 | 2024-02-20 | 上海凌达生物医药有限公司 | Amino substituted aromatic heterocyclic pyrazole compound, preparation method and application |
| WO2023020512A1 (en) * | 2021-08-16 | 2023-02-23 | 成都奥睿药业有限公司 | Substituted pyridine analogue, preparation method therefor, and use thereof as ahr modulator |
| WO2023033741A1 (en) * | 2021-09-02 | 2023-03-09 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| CN118076613A (en) * | 2021-09-02 | 2024-05-24 | 捷豹治疗有限公司 | Compounds useful for modulating AhR signaling |
| WO2023033742A1 (en) * | 2021-09-02 | 2023-03-09 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| CN115093400B (en) * | 2021-09-18 | 2023-09-05 | 北京华森英诺生物科技有限公司 | AhR inhibitor, application and preparation method thereof |
| WO2023060227A1 (en) | 2021-10-07 | 2023-04-13 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CN115925684A (en) * | 2021-12-03 | 2023-04-07 | 徐诺药业(南京)有限公司 | Pyrimidine derivative and preparation method and application thereof |
| WO2023135057A1 (en) | 2022-01-11 | 2023-07-20 | Deutsches Krebsforschungszentrum | Bicyclic triazine derivatives for the treatment of cancer |
| CN117624168A (en) * | 2022-08-19 | 2024-03-01 | 德明药泰生物技术（深圳）有限公司 | Condensed ring heterocyclic compound and preparation method and application thereof |
| WO2024076300A1 (en) | 2022-10-03 | 2024-04-11 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
| CN115804776A (en) * | 2022-12-16 | 2023-03-17 | 国纳之星(上海)纳米科技发展有限公司 | Application of aromatic hydrocarbon receptor inhibitor and 5-fluorouracil in combination in tumor treatment and inhibition drugs |
| CN116482278B (en) * | 2023-05-06 | 2024-02-09 | 广州清瑞生物科技有限责任公司 | Preparation method of reference substance for detecting acyclovir |
| CN117229284B (en) * | 2023-11-10 | 2024-02-06 | 上海泽德曼医药科技有限公司 | Tricyclic fused heterocyclic compound, preparation method and application thereof in medicine |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU747708B2 (en) * | 1996-07-24 | 2002-05-23 | Du Pont Pharmaceuticals Company | Azolo triazines and pyrimidines |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| WO2003024441A1 (en) | 2001-09-14 | 2003-03-27 | Shionogi & Co., Ltd. | Novel use of tricyclic compound |
| WO2002049651A1 (en) * | 2000-12-19 | 2002-06-27 | Merck Patent Gmbh | Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives |
| CN1310918C (en) * | 2002-09-04 | 2007-04-18 | 先灵公司 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| ATE378336T1 (en) * | 2002-09-19 | 2007-11-15 | Schering Corp | IMIDAZOPYRIDINES AS INHIBITORS OF CYCLIN DEPENDENT KINASES |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| JP2008520749A (en) | 2004-11-23 | 2008-06-19 | レディ ユーエス セラピューティックス， インコーポレイテッド | Novel bicyclic heterocyclic compound, process for its preparation, and composition comprising the novel bicyclic heterocyclic compound |
| DK2343320T3 (en) | 2005-03-25 | 2018-01-29 | Gitr Inc | ANTI-GITR ANTIBODIES AND APPLICATIONS THEREOF |
| DK2559690T3 (en) | 2005-05-10 | 2016-04-25 | Incyte Holdings Corp | Modulators of indoleamine 2,3-dioxygenase and methods of use thereof |
| SI1907424T1 (en) | 2005-07-01 | 2015-12-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| US20070078136A1 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| EP1971583B1 (en) | 2005-12-20 | 2015-03-25 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (en) | 2006-09-19 | 2008-02-08 | Incyte Corp | COMPOUNDS DERIVED FROM HETEROCICLO N-HIDROXIAMINO; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT CANCER, VIRAL INFECTIONS AND NEURODEGENERATIVE DISORDERS BETWEEN OTHERS. |
| WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| AU2007316417B2 (en) * | 2006-11-06 | 2013-08-22 | Tolero Pharmaceuticals, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| EP2175884B8 (en) | 2007-07-12 | 2017-02-22 | GITR, Inc. | Combination therapies employing gitr binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
| ES2462642T3 (en) * | 2007-12-14 | 2014-05-26 | F. Hoffmann-La Roche Ag | New derivatives of imidazo [1,2-a] pyridine and imidazo [1,2-b] pyridazine |
| US20110176972A1 (en) | 2008-05-29 | 2011-07-21 | Saint-Gobain Centre De Recherches et D'Etudes Eur | Cellular structure containing aluminium titanate |
| AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
| PE20100362A1 (en) | 2008-10-30 | 2010-05-27 | Irm Llc | PURINE DERIVATIVES THAT EXPAND HEMATOPOYETIC STEM CELLS |
| CN108997498A (en) | 2008-12-09 | 2018-12-14 | 霍夫曼-拉罗奇有限公司 | Anti- PD-L1 antibody and they be used to enhance the purposes of T cell function |
| LT3023438T (en) | 2009-09-03 | 2020-05-11 | Merck Sharp & Dohme Corp. | Anti-gitr antibodies |
| US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
| MY159679A (en) | 2009-12-10 | 2017-01-13 | Hoffmann La Roche | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| NZ602161A (en) | 2010-03-04 | 2014-12-24 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| KR101647871B1 (en) | 2010-03-05 | 2016-08-11 | 에프. 호프만-라 로슈 아게 | Antibodies against human csf-1r and uses thereof |
| MX2012010014A (en) | 2010-03-05 | 2012-09-21 | Hoffmann La Roche | Antibodies against human csf-1r and uses thereof. |
| TR201900368T4 (en) | 2010-05-04 | 2019-02-21 | Five Prime Therapeutics Inc | Antibodies that bind to Csf1r. |
| RU2710717C2 (en) | 2010-09-09 | 2020-01-10 | Пфайзер Инк. | Molecules which bind to 4-1bb |
| WO2012044562A2 (en) * | 2010-09-30 | 2012-04-05 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine pde10 inhibitors |
| KR20230133410A (en) | 2010-12-09 | 2023-09-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Use of chimeric antigen receptor-modified t cells to treat cancer |
| NO2694640T3 (en) | 2011-04-15 | 2018-03-17 | ||
| LT2699264T (en) | 2011-04-20 | 2018-07-10 | Medimmune, Llc | Antibodies and other molecules that bind b7-h1 and pd-1 |
| US9802937B2 (en) * | 2011-04-21 | 2017-10-31 | Origenis Gmbh | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors |
| KR101981873B1 (en) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | Anti-pd-l1 antibodies and uses thereof |
| CA2858069C (en) | 2011-12-08 | 2020-02-11 | Fred Hutchinson Cancer Research Center | Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells |
| CN104159921B (en) | 2011-12-15 | 2018-05-04 | 霍夫曼-拉罗奇有限公司 | Antibody for people CSF-1R and application thereof |
| MX2014008961A (en) | 2012-02-06 | 2014-10-14 | Genentech Inc | Compositions and methods for using csf1r inhibitors. |
| AR090263A1 (en) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME |
| AR090650A1 (en) * | 2012-04-12 | 2014-11-26 | Alcon Res Ltd | TREATMENT FOR INFLAMMATORY RESPONSES INDUCED BY EYE MICROBES |
| CA2871445C (en) | 2012-05-11 | 2020-07-07 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| UY34887A (en) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
| CN107759690A (en) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | With the method for the Antybody therapy symptom for combining the acceptor of colony stimulating factor 1 (CSF1R) |
| WO2014060112A1 (en) | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Pyrazolo[4,3-d]pyrimidines as kinase inhibitors |
| WO2014138485A1 (en) * | 2013-03-08 | 2014-09-12 | Irm Llc | Ex vivo production of platelets from hematopoietic stem cells and the product thereof |
| SG11201908624SA (en) | 2017-04-12 | 2019-10-30 | Magenta Therapeutics Inc | Aryl hydrocarbon receptor antagonists and uses thereof |
| MX2019012431A (en) | 2017-04-21 | 2020-08-03 | Ikena Oncology Inc | Indole ahr inhibitors and uses thereof. |
-
2018
- 2018-04-20 MX MX2019012431A patent/MX2019012431A/en unknown
- 2018-04-20 BR BR112019021992A patent/BR112019021992A2/en unknown
- 2018-04-20 EP EP18787414.4A patent/EP3612030A4/en active Pending
- 2018-04-20 AU AU2018256459A patent/AU2018256459B2/en active Active
- 2018-04-20 TW TW107113564A patent/TWI778050B/en active
- 2018-04-20 KR KR1020197034489A patent/KR102668371B1/en active IP Right Grant
- 2018-04-20 JP JP2020507495A patent/JP7232244B2/en active Active
- 2018-04-20 US US15/958,586 patent/US10570138B2/en active Active
- 2018-04-20 WO PCT/US2018/028532 patent/WO2018195397A2/en active Application Filing
- 2018-04-20 CN CN201880038301.XA patent/CN110831600B/en active Active
- 2018-04-20 SG SG11201909710X patent/SG11201909710XA/en unknown
- 2018-04-20 CA CA3059939A patent/CA3059939A1/en active Pending
-
2019
- 2019-10-16 ZA ZA2019/06822A patent/ZA201906822B/en unknown
- 2019-10-17 IL IL270025A patent/IL270025B2/en unknown
- 2019-10-18 CO CONC2019/0011584A patent/CO2019011584A2/en unknown
- 2019-10-21 CL CL2019003015A patent/CL2019003015A1/en unknown
- 2019-10-30 US US16/668,070 patent/US10689388B1/en active Active
-
2020
- 2020-04-08 US US16/843,606 patent/US11358969B2/en active Active
-
2022
- 2022-05-06 US US17/662,246 patent/US20230028336A1/en active Pending
- 2022-06-06 JP JP2022091740A patent/JP2022116319A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20200331917A1 (en) | 2020-10-22 |
| AU2018256459A1 (en) | 2019-11-07 |
| IL270025B1 (en) | 2023-01-01 |
| JP2020517734A (en) | 2020-06-18 |
| WO2018195397A2 (en) | 2018-10-25 |
| EP3612030A4 (en) | 2021-04-28 |
| CN110831600B (en) | 2023-10-17 |
| US10689388B1 (en) | 2020-06-23 |
| CN110831600A (en) | 2020-02-21 |
| JP2022116319A (en) | 2022-08-09 |
| JP7232244B2 (en) | 2023-03-08 |
| BR112019021992A2 (en) | 2020-06-09 |
| WO2018195397A3 (en) | 2018-12-13 |
| CL2019003015A1 (en) | 2020-03-27 |
| CA3059939A1 (en) | 2018-10-25 |
| US20180327411A1 (en) | 2018-11-15 |
| TWI778050B (en) | 2022-09-21 |
| AU2018256459B2 (en) | 2023-12-07 |
| EP3612030A2 (en) | 2020-02-26 |
| KR20190141722A (en) | 2019-12-24 |
| MX2019012431A (en) | 2020-08-03 |
| US20230028336A1 (en) | 2023-01-26 |
| TW201841917A (en) | 2018-12-01 |
| CO2019011584A2 (en) | 2020-02-18 |
| KR102668371B1 (en) | 2024-05-28 |
| US10570138B2 (en) | 2020-02-25 |
| IL270025A (en) | 2019-12-31 |
| IL270025B2 (en) | 2023-05-01 |
| US11358969B2 (en) | 2022-06-14 |
| ZA201906822B (en) | 2024-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909710XA (en) | Indole ahr inhibitors and uses thereof | |
| SG11201808799SA (en) | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201808682XA (en) | Silicone atoms containing ivacaftor analogues | |
| SG11201805449PA (en) | Methods of making chimeric antigen receptor -expressing cells | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201808751SA (en) | T cell receptors | |
| SG11201811643TA (en) | Compounds and methods for modulating rna function | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201908624SA (en) | Aryl hydrocarbon receptor antagonists and uses thereof | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201900545TA (en) | Pharmaceutical compounds | |
| SG11201901251SA (en) | Aminopyrimidines as alk inhibitors | |
| SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | |
| SG11201909376TA (en) | Crystalline forms of a jak inhibitor compound |